RYBELSUS® tablets, for oral use, contain semaglutide, a GLP-1 receptor agonist. The peptidebackbone is produced by yeast fermentation. The main protraction mechanism of semaglutide isalbumin binding, facilitated by modification of position 26 lysine with a hydrophilic spacer anda C18 fatty di-acid. Furthermore, semaglutide is modified in position 8 to provide stabilizationagainst degradation by the enzyme dipeptidyl-peptidase 4 (DPP-4). A minor modification wasmade in position 34 to ensure the attachment of only one fatty di-acid. The molecular formula isC187H291N45O59 and the molecular weight is 4113.58 g/mol.